|
Originally published In Press as doi:10.1074/jbc.M102166200 on April 30, 2001
J. Biol. Chem., Vol. 276, Issue 26, 23838-23848, June 29, 2001
The Homeodomain Proteins PBX and MEIS1 Are Accessory Factors That
Enhance Thyroid Hormone Regulation of the Malic Enzyme Gene in
Hepatocytes*
Yutong
Wang,
Liya
Yin, and
F. Bradley
Hillgartner
From the Department of Biochemistry, School of Medicine, West
Virginia University, Morgantown, West Virginia 26506
Received for publication, March 9, 2001, and in revised form, April 25, 2001
 |
ABSTRACT |
Triiodothyronine (T3) stimulates a
robust increase (>40-fold) in transcription of the malic enzyme gene
in chick embryo hepatocytes. Previous work has shown that optimal T3
regulation of malic enzyme transcription is dependent on the presence
of an accessory element (designated as region E) that immediately
flanks a cluster of five T3 response elements in the malic enzyme gene.
Here, we have analyzed the binding of nuclear proteins to region E and
investigated the mechanism by which region E enhances T3
responsiveness. In nuclear extracts from hepatocytes, region E binds
heterodimeric complexes consisting of the homeodomain proteins PBX and
MEIS1. Region E contains four consecutive PBX/MEIS1 half-sites.
PBX-MEIS1 heterodimers bind the first and second half-sites, the third
and fourth half-sites, and the first and fourth half-sites. The
configuration conferring the greatest increase in T3 responsiveness
consists of the first and fourth half-sites that are separated by 7 nucleotides. Stimulation of T3 response element functions by region E
does not require the presence of additional malic enzyme sequences. In
pull-down experiments, PBX1a and PBX1b specifically bind the nuclear T3
receptor- , and this interaction is enhanced by the presence of T3. A
T3 receptor- region containing the DNA binding domain plus
flanking sequences (amino acids 21-157) is necessary and sufficient
for binding to PBX1a and PBX1b. These results indicate that
PBX-MEIS1 complexes interact with nuclear T3 receptors
to enhance T3 regulation of malic enzyme transcription in hepatocytes.
 |
INTRODUCTION |
Malic enzyme catalyzes the oxidative decarboxylation of malate to
pyruvate and CO2, simultaneously generating NADPH from
NADP+. This reaction is the primary source of reducing
equivalents for de novo synthesis of long chain fatty acids
in avian liver (1). Regulation of malic enzyme activity is typical of
that of other lipogenic enzymes. Malic enzyme activity increases by 70-fold when previously starved chicks are fed a high carbohydrate, low
fat diet and dramatically decreases when animals are starved (2).
Nutritional regulation of malic enzyme activity is quantitatively mimicked in primary cultures of chick embryo hepatocytes by
manipulating the concentrations of hormones and metabolic fuels in the
culture medium. Insulin, glucose, and 3,5,3'-triiodothyronine
(T3),1 humoral factors that
are elevated during consumption of a high carbohydrate, low fat diet,
increase malic enzyme activity in chick embryo hepatocytes (3, 4). T3
alone stimulates malic enzyme activity; insulin and glucose amplify the
action of T3 but have little effect when added by themselves. Glucagon
and fatty acids, humoral factors that are elevated during starvation, inhibit the stimulation of malic enzyme activity caused by T3 (3, 5).
Alterations in malic enzyme activity caused by nutritional manipulation
in vivo and nutrients and hormones in culture are mediated
primarily by changes in the rate of transcription of the malic enzyme
gene (4-7).
In addition to regulation by nutrients and hormones, malic enzyme
transcription is controlled in a tissue-specific or cell type-specific
manner. In chicks fed a high carbohydrate, low fat diet, malic enzyme
transcription is high in liver and low in heart, kidney, and brain (6).
Nutritional manipulation has no effect on malic enzyme transcription in
heart, kidney, and brain. Cell type-dependent differences
in the regulation of malic enzyme are also observed in cells in
culture. T3 stimulates a 40-fold or greater increase in malic enzyme
transcription in chick embryo hepatocytes, whereas in chick embryo
fibroblasts and quail QT6 cells, T3 has little or no effect on malic
enzyme transcription (8).
The robust effects of T3 on malic enzyme transcription in chick embryo
hepatocytes makes this an excellent system to study the molecular
mechanisms by which T3 regulates transcription. T3 activates gene
transcription by interacting with nuclear T3 receptors (TR) (9, 10).
TRs bind T3 response elements (T3RE) of target genes as homodimers or
heterodimers with the retinoid X receptor (RXR). T3REs consist of
multiple copies of a hexameric sequence related to a consensus RGGWMA
arranged as inverted repeats, everted repeats, direct repeats, or as
extended single copies of the hexamer (11). The T3-induced increase in
malic enzyme transcription in chick embryo hepatocytes is mediated by
at least six T3REs (12-14). One strongly active and four weakly active
T3REs are clustered in a 109-bp region located at 3878/ 3769 bp
relative to the transcription start site. This cluster of T3REs is
referred to as a T3 response unit (T3RU). Another weakly active T3RE is located about 700 bp downstream of the T3RU. All of the malic enzyme
T3REs consist of directly repeated hexameric half-sites separated by a
4-bp spacer and bind TR-RXR heterodimers in hepatic nuclear extracts.
In addition to T3REs, accessory elements that bind nonreceptor proteins
play an important role in mediating the effects of T3 on malic enzyme
transcription. We have identified four accessory elements in the malic
enzyme gene that confer differences in T3 regulation of malic enzyme
transcription between chick embryo hepatocytes and chick embryo
fibroblasts (15). Each element enhances T3 responsiveness of the malic
enzyme promoter in chick embryo hepatocytes but has no effect on T3
responsiveness in chick embryo fibroblasts. Three of the accessory
elements immediately flank the T3RU and are designated regions A, E,
and F. The T3RU and accessory elements A, E, and F overlap with a
hepatocyte-specific and T3-inducible region of DNase I hypersensitivity
in chromatin. Region F ( 3703/ 3686 bp) binds the liver-enriched
factor, CCAAT/enhancer-binding protein- (C/EBP ). The identities
of the proteins that bind region A ( 3895/ 3890 bp) and region E
( 3761/ 3744 bp) have not yet been determined. The nature of the
proteins that bind region E is of particular interest because mutation
of this element causes the largest decrease in T3-induced malic enzyme
transcription of the four accessory elements identified.
PBX proteins are members of the 3-amino acid loop extension superclass
of homeodomain proteins (16). The pbx1 gene was first identified as a site of t(1,19) chromosomal translocation leading to
the production of an E2a-PBX1 fusion protein in a subset of pre-B cell
acute lymphoblastic leukemias in humans (17, 18). Highly conserved
homologs of PBX have been identified in Drosophila melanogaster (19), Caenorhabditis elegans (16), and
zebrafish (20). Genetic and biochemical analyses have shown that PBX
proteins regulate developmental pathways by serving as cofactors for
other homeodomain transcription factors. For example, PBX potentiates the effects of HOX proteins on segmentation along the
anterior-posterior axis (21). This effect is mediated by heterodimeric
interactions between PBX and HOX. PBX-HOX complexes bind DNA with
enhanced specificity and affinity compared with complexes containing
PBX or HOX alone (22-24). PBX also binds cooperatively to DNA with other 3-amino acid loop extension class homeodomain proteins including MEIS1 and the closely related factor, PREP1 (also referred to as pKnox)
(25-28). Complexes containing PBX-MEIS1 or PBX-PREP1 are components of
the transcriptional network controlling cell fate and segmental
patterning during embryonic development (29-31).
Recent studies have shown that PBX, MEIS1, and PREP1 also
function in maintaining cellular differentiation in adult tissues. For
example, PBX-PREP1 heterodimers mediate the pancreatic-specific transcription of the genes for somatostatin and glucagon (32, 33). In
the case of the somatostatin gene, PBX-PREP1 stimulates transcription
in pancreatic cells by potentiating the transcriptional activity of the
pancreatic-specific homeodomain factor, PDX1 (32). In the case of the
glucagon gene, PBX-PREP1 binds to a cis-acting element that
represses glucagon transcription in non-pancreatic cells without
affecting glucagon transcription in pancreatic cells (33). Other work
(34) has shown that a PBX-MEIS-PDX1 trimeric complex activates
transcription of the elastase I gene in pancreatic acinar cells via
interactions with the acinar cell-specific factor, PTF1. Still other
studies have shown that PBX-PREP1 heterodimers interact with a
cis-acting element that confers cell type-specific transcription of the
human 2(V) collagen gene (35). In addition to the pancreas and
tissues that express 2(V) collagen, PBX and MEIS1/PREP1 proteins are
expressed at significant levels in other adult tissues, including liver
(36-40). The physiological role of these proteins in liver has not
been established.
In the present study, we have analyzed the binding of nuclear proteins
to malic enzyme region E in hepatocytes. We show that this TR accessory
element binds PBX-MEIS1 heterodimers in multiple configurations. In
addition, we have developed data suggesting that the stimulation of
T3-induced malic enzyme transcription by region E is mediated by direct
interactions between PBX and TR.
 |
EXPERIMENTAL PROCEDURES |
Plasmids--
The DNA fragments used to construct reporter
plasmids were named by designating the 5' and 3' ends of each fragment
relative to the start site of transcription of the malic enzyme gene.
p[ME 3921/ 3631]ME 147/+31CAT has been described previously (15).
This reporter plasmid contains the malic enzyme T3RU and flanking
sequences ( 3921 to 3631 bp) linked to the minimal promoter of the
malic enzyme gene ( 147 to +31 bp). Site-directed mutations were
introduced into p[ME 3921/ 3631]ME 147/+31CAT using a polymerase
chain reaction-based strategy (41). p[T3RE-2]ME 147/+31CAT was made
by subcloning the major malic enzyme T3RE between 3883 and 3858 bp
into the BamHI/SacI site upstream of the minimal promoter in ME 147/+31CAT. p[T3RE-2+Region E]ME 147/+31CAT was constructed by inserting region E (ME 3767/ 3742) into the
SpeI/SmaI site immediately downstream of the of
T3RE-2 in p[T3RE-2]ME 147/+31CAT. Dr. M. Kamps (University of
California, San Diego) provided the cDNAs for human PBX1a and
PBX1b. The cDNA for mouse MEIS1 was obtained by Dr. N. Copeland
(NCI-Frederick Cancer Research and Development Center). Drs. H. Chen
and S. Antonarakis (University of Geneva) supplied the cDNA for
human PREP1. cDNAs for full-length PBX1a (PBX1a-(1-430)), PBX1b
(PBX1b-(1-347)), MEIS1 (MEIS1-(1-390)), and PREP1 (PREP1-(1-436))
and human RXR (RXR -(1-462)) were subcloned into pSV-SPORT1 (Life
Technologies, Inc.). Expression plasmids containing N-terminal
truncations of PBX1a (PBX1a-(80-430) and PBX1a-(119-430)) were
provided by Dr. C. Murre (University of California, San Diego). The
full-length cDNA of chicken TR corresponding to amino acids
1-408 (TR -(1-408)) was subcloned into pGEM-3Zf( ) (Promega).
N-terminal and C-terminal deletion derivatives of chicken TR were
generated by polymerase chain reaction. Polymerase chain reaction
products encoding TR polypeptides containing amino acids 1-118,
1-157, 21-408, 51-408, and 120-408 were subcloned into pGEM-3Zf( ). To generate plasmids that express fusion proteins containing glutathione S-transferase (GST) linked to PBX1a,
PBX1b, or TR , cDNAs containing the full-length coding region of
PBX1a, PBX1b, or TR were subcloned into pGEX-2T (Amersham Pharmacia Biotech). Structures of reporter plasmids and expression plasmids were
confirmed by restriction enzyme mapping and nucleotide sequence analyses.
Cell Culture and Transient Transfection--
Primary cultures of
chick embryo hepatocytes were prepared as described previously (42) and
maintained in serum-free Waymouth medium MD705/1 containing 50 nM insulin (gift from Lilly) and corticosterone (1 µM). Hepatocytes were incubated at 40 °C in a
humidified atmosphere of 5% CO2 and 95% air. Cells were
transfected using a modification of the method of Baillie et
al. (43). Briefly, chick embryo hepatocytes were isolated as
described above and plated on 35-mm dishes. At 18 h of incubation,
the medium was replaced with one containing 20 µg of LipofectACE
(Life Technologies, Inc.), 3.0 µg of
p[ME 3921/ 3631]ME 147/+31CAT, or an equimolar amount of another
reporter plasmid and 0.05 µg of pCMV- -galactosidase. At
42 h of incubation, the transfection medium was replaced with fresh medium with or without T3 (1.5 µM). At
90 h of incubation, chick embryo hepatocytes were harvested, and
cell extracts were prepared for CAT (44) and -galactosidase (45)
measurements. CAT activity was expressed relative to -galactosidase
activity to correct for differences in transfection efficiency between samples. All DNAs used in transfection experiments were purified using
the Qiagen endotoxin-free kit.
Gel Mobility Shift Analysis--
Nuclear extracts were prepared
from chick embryo hepatocytes incubated with or without T3 for 24 h. Nuclei and nuclear extracts were prepared as described (46) except
that the protease inhibitors leupeptin (0.25 µg/ml), benzamidine (10 mM), and PMSF (0.5 mM) were added to the
extraction and dialysis buffers at the indicated concentrations. PBX1a,
PBX1b, MEIS1, PREP1, RXR , and TR were translated in
vitro using the TNT SP6-coupled reticulocyte lysate system
(Promega). Incorporation of [35S]methionine into PBX1a,
PBX1b, MEIS1, PREP1, RXR , and TR was measured in parallel
reactions in order to assess the relative efficiency of synthesis of
the different transcription factors.
Double-stranded oligonucleotides were prepared by combining equal
amounts of the complementary single-stranded DNA in a solution containing 10 mM Tris, pH 8.0, 1 mM EDTA
followed by heating to 95 °C for 2 min and then cooling to room
temperature. The annealed oligonucleotides were labeled by filling in
overhanging 5' ends using the Klenow fragment of Escherichia
coli DNA polymerase in the presence of
[ -32P]dCTP. Binding reactions were carried out in 20 µl containing 18 mM HEPES, pH 7.9, 90 mM KCl,
0.18 mM EDTA, 0.45 mM dithiothreitol, 18%
glycerol (v/v), 0.3 mg/ml bovine serum albumin, and 2 µg of poly(dI-dC). A typical reaction contained 20,000 cpm of labeled DNA and 10 µg of nuclear extract or 2 µg of in vitro
translated proteins. The reaction was carried out on ice for 60 min.
DNA and DNA-protein complexes were resolved on 6% nondenaturing
polyacrylamide gels at 4 °C in 0.5× TBE (45 mM Tris, pH
8.3, 45 mM boric acid, 1 mM EDTA). Following
electrophoresis, the gels were dried and subject to storage phosphor
autoradiography. For competition experiments, unlabeled competitor DNA
was mixed with radiolabeled oligomer prior to addition of nuclear
extract. For gel supershift experiments, nuclear extracts or in
vitro translated proteins were incubated with antibodies for
1 h at 0 °C prior to addition of the oligonucleotide probe. An
antiserum that reacts with all isoforms of PBX (PBX1, -2, and -3) (47)
was generously provided by Dr. M. Kamps (University of California, San
Diego). A polyclonal antibody that reacts with MEIS1 and PREP1
(sc-6245) was purchased from Santa Cruz Biotechnology. Synthetic
oligonucleotides that were used as probes or competitors in gel
mobility shift assays are listed in Fig. 3.
Protein-Protein Interactions--
GST or GST fusion proteins
were expressed in E. coli (BL21, pLysS) and purified using
standard techniques (48). Briefly, bacteria were transformed with
pGEX-2T or recombinant pGEX-2T plasmids expressing GST fusion proteins.
Overnight bacterial cultures in ampicillin (250 µg/ml) were diluted
1:100 into 250 ml of Luria broth and grown at 37 °C to an
A600 = 1.0 before induction with 1 mM isopropylthiogalactopyranoside for 60 min. Cells were
pelleted and resuspended in 5 ml of buffer A (50 mM KCl, 25 mM HEPES, pH 7.9, 6% glycerol, 5 mM EDTA, 5 mM MgCl2, 1 mM dithiothreitol, 0.05% Triton X-100). Cells were lysed on ice by sonication and centrifuged at 12,000 × g for 10 min at 4 °C. The
supernatant was mixed for 1 h at 4 °C on a rotator with 0.5-1
ml of 50% glutathione-Sepharose beads (Amersham Pharmacia Biotech)
that were preswollen in buffer A. After absorption, beads were
collected by centrifugation at 4 °C and washed three times with 1 ml
of buffer A. Fusion proteins coupled to the glutathione-Sepharose beads
were stored at 4 °C as 50% (v/v) slurry in buffer A. The
concentrations and sizes of GST and GST fusion proteins were estimated
by SDS-PAGE, using a known quantity of molecular weight standards.
L-[35S]Cysteine- or
L-[35S]methionine-labeled proteins were
prepared by using TNT reticulocyte lysates (Promega). Approximately 2.5 × 104 to 5 × 104 cpm of
35S-labeled protein were incubated with 100 ng of GST
fusion protein immobilized on glutathione-Sepharose beads in 300 µl
of buffer A for 1 h at 4 °C on a rotator. Beads were collected
by centrifugation at 4 °C and washed three times with 1 ml of buffer
A. The bound proteins were eluted with SDS-gel loading buffer and
analyzed by SDS-PAGE followed by storage phosphor autoradiography.
Where indicated 1 µM T3 or 9-cis-retinoic acid
was included in the binding reaction mixture. 35S-Labeled
proteins were analyzed by electrophoresis and storage phosphor
autoradiography to ensure that similar levels of input radioactivity of
the labeled protein were used in the GST binding assays.
 |
RESULTS |
PBX/MEIS1 Heterodimers Bind Region E of the Malic Enzyme
Gene--
Previous work (25-28) has shown that PBX binds DNA as
heterodimers with other homeodomain factors such as MEIS1 and PREP1 in terminally differentiated cells. PBX, MEIS1, and PREP1 interact with
4-bp sequence elements referred to as half-sites. Selection studies
with degenerate oligonucleotides have shown that PBX-MEIS1 and
PBX-PREP1 heterodimers bind two contiguous half-sites with the
consensus sequence, 5'-TGAT-TGAC-3', in which PBX contacts the upstream
half-site and MEIS1/PREP1 contacts the downstream half-site (Fig.
1A) (27, 47). This sequence is
referred to as the PBX-cooperativity element (PCE). Analysis of the
sequence in region E indicated the presence of four tetrameric sequence elements that are identical or strongly resemble binding sites for PBX,
MEIS1, and PREP1. These half-sites are designated 1, 2, 3, and 4. To
investigate whether PBX heterodimers interacted with region E, gel
mobility shift experiments were performed using antibodies against PBX
and MEIS1/PREP1. Incubation of a 32P-labeled
oligonucleotide probe containing region E with nuclear extract from
chick embryo hepatocytes resulted in the formation of two protein-DNA
complexes that were designated a and b in the order of increasing
mobility (Fig. 1B). The pattern of protein binding to region
E was similar in hepatocytes incubated in the absence and presence of
T3 (data not shown) (15). Incubation of hepatocyte nuclear extracts
with antiserum against all isoforms of PBX completely disrupted the
formation of complex a and b, indicating that these complexes contained
PBX or a highly related factor. Incubation of nuclear extracts with an
antibody that reacts with MEIS1 and PREP1 also completely disrupted the
formation of complex a and complex b. These data indicate that complex
a and complex b contain PBX-MEIS1 and/or PBX-PREP1 heterodimers.
Further evidence that PBX-MEIS1 and/or PBX-PREP1 bound region E in
hepatocytes was obtained from competition experiments. An unlabeled
oligonucleotide containing the PCE was as effective as an unlabeled
oligonucleotide containing region E in competing for the binding of
complex a and complex b (Fig. 3B).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Characterization of proteins that
bind to region E using the gel mobility shift assay. A,
comparison of the sequence of malic enzyme region E with the PBX
cooperativity sequence (PCE). The four potential tetrameric
half-sites are overlined. B, gel mobility shift
experiments were performed using nuclear extracts prepared from chick
embryo hepatocytes (CEH). A double-stranded DNA fragment
containing region E ( 3767 to 3742 bp) was labeled with
[ -32P]dCTP using the Klenow fragment of E. coli DNA polymerase. The radiolabeled probe was incubated with
nuclear extract as described under "Experimental Procedures." DNA
and DNA-protein complexes were resolved on 6% nondenaturing
polyacrylamide gels. Nuclear extracts were incubated with antibodies
against PBX and MEIS1/PREP1 prior to the addition of the probe.
Positions of the specific DNA-protein complexes and supershifted
complexes are indicated by arrows. These data are
representative of three different experiments employing independent
preparations of nuclear extract. PI serum, preimmune
serum.
|
|
The ability of region E to bind heterodimers containing PBX-MEIS1 and
PBX-PREP1 was confirmed by gel mobility shift experiments employing
in vitro synthesized transcription factors. At least 5 isoforms of PBX have been identified that are derived from three different genes (17, 18, 36). PBX1a, PBX2, and PBX3a are products of
the pbx1, pbx2, and pbx3 genes,
respectively. PBX1b and PBX3b are variants that arise from alternative
processing. As PBX1a and PBX1b are expressed in hepatic cells (36-38),
we investigated whether these proteins bound region E in the absence or
presence of MEIS1 and PREP1. Incubation of in vitro
translated human PBX1a, human PBX1b, mouse MEIS1, or human PREP1 with
the region E probe resulted in no specific binding activity (Fig.
2). Inclusion of MEIS1 in the binding
reactions with PBX1a and PBX1b stimulated the formation of high
affinity protein-DNA complexes containing PBX1a-MEIS1 and PBX1b-MEIS1,
respectively. Inclusion of PREP1 in the binding reactions with PBX1a
and PBX1b also stimulated the formation of high affinity heterodimeric
complexes. Thus, PBX1a and PBX1b bind region E cooperatively with MEIS1
or PREP1. Cooperative interactions between PBX1 and MEIS1 and between
PBX1 and PREP1 have been reported for other PBX-binding sites (25-28, 32, 33). The mobilities of the protein-DNA complexes containing PBX1a-PREP1 and PBX1b-PREP1 were slower than the mobilities of corresponding complexes containing PBX1a-MEIS1 and PBX1b-MEIS1. This
was due to the larger size of PREP1 (436 amino acids) relative to MEIS1
(390 amino acids). Interestingly, the mobility of complex a in
hepatocyte nuclear extracts was identical to that of PBX1a-MEIS1 and
the mobility of complex b was identical to that of PBX1b-MEIS1. Assuming that the sizes of chicken PBX1a, PBX 1b, MEIS1, and PREP1 are
similar to their corresponding mammalian homologs, we propose that
complex a and complex b contain PBX1a-MEIS1 and PBX1b-MEIS1, respectively. Complex a may also contain PBX2-MEIS1 heterodimers, as
PBX2 is approximately the same size of PBX1a, is expressed in liver,
and binds DNA cooperatively with MEIS1 (25, 27, 36). Because expression
of PBX3a and PBX3b in liver is very low compared with that of PBX1 and
PBX2 (36), the former proteins are not likely to be present in
complex a and complex b.

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 2.
PBX1a and PBX1b bind region E cooperatively
with MEIS1 or PREP1. Gel mobility shift assays were performed as
described under "Experimental Procedures" using
32P-labeled region E ( 3767 to 3742 bp) as the probe. In
lanes 3-6 and lanes 8-15, equimolar amounts of
in vitro translated PBX1a or PBX1b were incubated in the
absence or presence of in vitro translated MEIS1 or PREP1 as
indicated. In lane 7, the 32P-labeled probe was
incubated with nuclear extract from chick embryo hepatocytes
(CEH). In lanes 11 and 12, in
vitro synthesized proteins were incubated with antibodies against
PBX or MEIS1/PREP1 prior to the addition of the probe. In lanes
13 and 14, competition analysis was performed with a
100-fold molar excess of unlabeled competitor DNA. Arrows
indicate the binding of complex a and complex b in chick embryo
hepatocytes nuclear extracts. The bracket indicates the
binding of specific complexes formed from in vitro
translated proteins. Asterisks indicate the binding of
endogenous complexes in lysates.
|
|
Identification of Sequences in Region E That Bind PBX/MEIS1
Heterodimers in Nuclear Extracts from Hepatocytes--
In the bovine
cyp17 gene, PBX-MEIS1 interacts with a cAMP-responsive
sequence (CRS-1) that consists of tandem 4-bp half-sites with no spacer
between the half-sites (28). Studies with artificial sequence elements
have shown that PBX1-MEIS1 can also bind tandem half-sites that are
separated by 3 or 6 nucleotides (49). The sequence in region E contains
five possible binding configurations for PBX-MEIS1 heterodimers (Fig.
3A). Two of the binding
configurations are composed of two half-sites with no spacer
(i.e. sites 1 and 2 and sites 3 and 4), another two binding
configurations are composed of two half-sites separated by a 3-bp
spacer (i.e. sites 1 and 3 and sites 2 and 4), and one
binding configuration contains two half-sites separated by a 7-bp
spacer (i.e. sites 1 and 4). To determine which of these
configurations bind complex a and complex b, competition experiments
were performed with oligonucleotide competitors containing mutations in
specific half-sites. Mutation of site 1 (mut E 1), site 2 (mut E 2), or
site 3 (mut E 3) had little or no effect on the binding affinity of
complex a and complex b, whereas mutation of site 4 (mut E 4) decreased
the binding affinity of complex a and complex b (Fig. 3B).
These results suggest that complex a and complex b bind region E in two
or more configurations involving site 4. To delineate further the
region E binding configurations, competition analyses were conducted
with oligonucleotides containing specific mutations in two of the four
half-sites. Mutation of sites 1 and 3 (mut E 1/3), sites 1 and 4 (mut E
1/4), and sites 2 and 4 (mut E 2/4) abolished protein binding to region
E. Mutation of sites 3 and 4 (mut E 3/4) inhibited but did not abolish
the binding of complex a and complex b to region E. Mutation of sites 1 and 2 and sites 2 and 3 had little or no effect on protein binding activity. Collectively, these data indicate that complex a and complex
b bind region E in the following configurations: half-sites 1 and 2, half-sites 1 and 4, and half-sites 3 and 4. The binding affinity of
complex a and complex b for half-sites 1 and 2 is lower than that for
half-sites 1 and 4 and half-sites 3 and 4. Competition analysis with
region E mutants indicated that in vitro synthesized
PBX1a-MEIS1 and PBX1b-MEIS1 bound region E in a manner identical to
that of complex a and complex b (data not shown). These data are
consistent with the proposal that complex a and complex b contain
PBX1a-MEIS1 and PBX1b-MEIS1, respectively.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
Complex a and complex b bind region E in
multiple configurations. Gel mobility shift experiments were
performed as described under "Experimental Procedures" using
32P-labeled region E ( 3767 to 3742 bp) as a probe and
nuclear extracts prepared from chick embryo hepatocytes. Nuclear
extracts were incubated with the region E probe in the presence of
different concentrations of unlabeled competitor DNAs. Each reaction
contained 10 µg of nuclear protein. DNA and DNA-protein complexes
were resolved on 6% nondenaturing polyacrylamide gels. A,
possible binding configurations of PBX-MEIS1 on region E. The
position of putative tetrameric half-sites in region E are indicated by
the boxes above the wild-type sequence for
region E. The half-sites are labeled 1-4. The
sequence of oligonucleotide competitors containing mutations of one or
more half-sites is also shown. Mut 1 to mut 4 refer to the number of
the half-site that was mutated in each oligonucleotide. The sequence of
the PCE is shown in Fig. 1A. B, competition
analysis with native and mutant forms of region E. Unlabeled competitor
DNAs (2-, 5-, 20-, or 50-fold molar excess) were mixed with the
radiolabeled probe prior to the addition of nuclear extract. Complex
a and complex b are indicated by arrows. These data are
representative of four experiments employing independent preparations
of nuclear extract.
|
|
Each of the PBX1-MEIS1 binding configurations on region E
overlaps with each other suggesting that complex a and complex b are
dimeric rather than tetrameric complexes. To confirm this supposition, gel mobility shift experiments were performed with region
E probes that contained mutations in half-sites 1 and 2 (mut E 1/2) or
half-sites 2 and 3 (mut E 2/3). Hepatic nuclear proteins and in
vitro synthesized PBX1a, PBX1b, and MEIS1 bound both of these
probes in a pattern identical to that of the wild-type region E probe
(data not shown). Thus, protein binding to region E represents dimers
of PBX1a, PBX1b, and MEIS1 and not higher order structures of these proteins.
Next, we investigated the effects of site-specific mutations of region
E on T3 responsiveness in chick embryo hepatocytes. Hepatocytes were
transiently transfected with reporter constructs containing mutations
of two of the four half-sites of region E in the context of
p[ME 3921/ 3631]ME 147/+31CAT. A block mutation of region E
extending from 3761 to 3744 (mut E block, Fig. 3A) inhibited T3 responsiveness by 58% (Fig.
4). This effect was due to a decrease in
promoter activity in the presence of T3. Site-specific mutations that
abolished protein binding to region E (i.e. mut E 1/3, mut E
1/4, and mut E 2/4) also inhibited T3 responsiveness, and the extent of
this inhibition was similar to that of the block mutation of region E. Thus, site-specific mutations that blocked protein binding to region E
also blocked the ability of region E to stimulate T3 responsiveness.
Site-specific mutations that had no effect (i.e. mut E 1/2
and mut E 2/3) or partially inhibited (i.e. mut E 3/4)
protein binding to region E conferred a higher level of T3
responsiveness than mutations that abolished protein binding to region
E (i.e. mut E block, mut E 1/3, mut E 1/4, and mut E 2/4).
Mut E 2/3 conferred the highest level of T3 responsiveness of all of
the mutations examined. These data indicate that all three PBX-MEIS1
binding configurations on region E are capable of enhancing T3
responsiveness directed by the upstream region of the malic enzyme gene
and that binding to half-sites 1 and 4 results in the greatest
stimulation of T3 responsiveness. Interestingly, the latter
configuration perfectly matches the consensus binding sequence for
PBX1-MEIS1 heterodimers (i.e. TGATTGAC) (26, 27) except that
the tetrameric half-sites are separated by a 7-bp spacer. This is the
first description of a native PBX1-MEIS1-binding sequence with this
arrangement of half-sites.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 4.
Stimulation of T3 responsiveness by region E
is correlated with complex a and complex b binding activity.
p[ME 3921/ 3631]ME 147/+31CAT or constructs containing mutations
of region E in the context of p[ME 3921/ 3631]ME 147/+31CAT were
transiently transfected into chick embryo hepatocytes as described
under "Experimental Procedures." Transfections also contained
CMV- -galactosidase as a control for transfection efficiency. After
the transfection, cells were treated with or without T3 for 48 h.
Cells were then harvested, extracts prepared, and CAT and
-galactosidase assays performed. Left, the constructs
used in these experiments. Numbers indicate the 5' or 3' boundaries of
malic enzyme DNA in nucleotides relative to the start site for
transcription. The mutated sequences in region E are shown in Fig.
3A. Right, CAT activity was expressed relative to
-galactosidase activity to correct for differences in transfection
efficiency. CAT activity in cells transfected with pME 147/+31CAT and
incubated without T3 was set at 1, and the other activities were
adjusted proportionately. The -fold stimulation by T3 was calculated by
dividing CAT activity in hepatocytes treated with T3 (+T3)
by that for hepatocytes not treated with T3 ( T3). The
-fold responses were calculated for individual experiments and then
averaged. The results are the means ± S.E. of 5 experiments. *,
the -fold stimulation by T3 was significantly higher than that of cells
transfected with p[ME 3921/ 3631] ME 147/+31CAT containing mut E
block (p < 0.05).
|
|
Region E Alone Can Enhance T3 Regulation Directed by a
T3RE--
PBX-MEIS1 bound to region E ( 3762/ 3748 bp) may enhance
T3 regulation of malic enzyme transcription by interacting with TR-RXR heterodimers bound to the T3RU ( 3878/ 3769 bp). Alternatively, PBX-MEIS1 may enhance T3 responsiveness by interacting with other TR
accessory factors bound to sequences flanking the T3RU. For example,
PBX-MEIS1 may interact with C/EBP bound to region F ( 3703/ 3686
bp). To assess the role of these possible mechanisms of PBX-MEIS1
action, transient transfection experiments were conducted to determine
whether region E alone could enhance T3 regulation of transcription
conferred by a T3RE. Within the malic enzyme T3RU is a strongly active
T3RE designated as T3RE-2 ( 3878/ 3863 bp). When hepatocytes were
transfected with a reporter plasmid containing T3RE-2 linked to the
minimal promoter of the malic enzyme gene (p[T3RE-2]ME 147/+31CAT),
T3 stimulated a 10-fold increase in promoter activity (Fig.
5). When a DNA fragment containing region
E ( 3767/ 3742 bp) was inserted downstream of T3RE-2 in p[T3RE-2]ME 147/+31CAT, the T3-induced stimulation of promoter activity was increased to 47-fold. The increase in T3 responsiveness caused by region E was due to an increase in promoter activity in the
presence of T3. Insertion of DNA fragment containing mut E block
downstream of T3RE-2 in p[T3RE-2]ME 147/+31CAT had no effect on T3
responsiveness, indicating that the increase in T3 responsiveness
caused by region E was not due to changes in the spacing between T3RE-2
and the minimal malic enzyme promoter. Region E also enhanced T3
responsiveness when it was ligated downstream to the malic enzyme T3RU
in p[ME 3921/ 3768]ME 147/+31CAT (data not shown). These data
indicate that the stimulation of T3-induced malic enzyme transcription
caused by region E is mediated, at least in part, by interactions
between PBX-MEIS1 and TR-RXR.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 5.
Region E alone can enhance T3 regulation
directed by a T3RE. Oligonucleotides containing region E ( 3767
to 3742 bp) or a block mutation of region E (mut E block) were
inserted downstream of malic enzyme T3RE-2 in
p[T3RE-2]ME 147/+31CAT. Hepatocytes were transiently transfected
with these constructs and treated with or without T3 as described in
the legend to Fig. 4 and under "Experimental Procedures."
Left, constructs used in these experiments. The sequence for
region E and mut E block are shown in Fig. 3A.
Right, CAT activity in cells transfected with
p[T3RE-2]ME 147/+31CAT and treated without T3 was set at 1, and the
other activities were adjusted proportionately. The -fold stimulation
by T3 was calculated as described in the legend in Fig. 4. The results
are the means ± S.E. of 5 experiments. *, the -fold stimulation
by T3 for p[T3RE-2+Region E]ME 147/+31CAT was significantly higher
than that of any other construct (p < 0.05).
|
|
PBX1 Physically Interacts with TR--
Previous studies have
demonstrated that PBX-MEIS1 heterodimers function as cofactors for
other transcription factors (50). For example, PBX1-MEIS1 bound to a
PCE strongly augments transcriptional activation by MyoD or myogenin
containing complexes bound to an adjacent E box motif. This effect of
PBX1-MEIS1 is mediated, in part, by direct interactions between the
PBX1 homeodomain and a highly conserved tryptophan motif flanking the
basic helix-loop-helix domain of MyoD and myogenin. These findings
coupled with the close proximity of region E to the T3RU led us to
hypothesize that PBX1-MEIS1 enhanced T3 responsiveness of malic enzyme
transcription by directly interacting with TR-RXR. To investigate this
hypothesis, we determined whether PBX1 or MEIS1 physically interacted
with TR and RXR using a pull-down assay. In our initial experiments, we
investigated the ability of in vitro synthesized TR and
RXR to bind a bacterially expressed fusion protein containing
glutathione S-transferase (GST) linked to PBX1a.
35S-Labeled TR bound to GST-PBX1a, and the presence of
T3 enhanced this interaction (Fig.
6B). 35S-Labeled
TR also interacted with GST-PBX1b in a T3-regulated manner (Fig.
6C). Inclusion of unlabeled RXR in the binding reaction had no effect on the interaction of 35S-labeled TR with
GST-PBX1a and GST-PBX1b (data not shown). No interaction was observed
between 35S-labeled TR and GST. In contrast to the
results for TR , little or no interaction was observed between
35S-labeled RXR and GST-PBX1a (Fig. 6B) and
between 35S-labeled RXR and GST-PBX1b (Fig.
6C). The lack of interaction between RXR and PBX1
proteins was confirmed by pull-down experiments employing GST-RXR as
the bait and 35S-labeled PBX1a and PBX1b synthesized
in vitro (data not shown). These data indicate that PBX1a
and PBX1b selectively interact with TR of the TR-RXR heterodimeric
complex.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
TR interacts with
PBX1a and PBX1b in a T3-regulated manner. A, schematic
representation of PBX1a and PBX1b. The MEIS cooperativity domain
(MCD) and homeodomain (HD) region are indicated.
B, TR interacts with GST-PBX1a. Bacterially produced GST
or GST-PBX1a immobilized on glutathione-Sepharose beads was incubated
with in vitro translated and 35S-labeled TR
or RXR as described under "Experimental Procedures." Incubations
were performed in the absence and presence of 1 µM T3 or
1 µM 9-cis-retinoic acid (9-cis RA)
as indicated. After the matrix was extensively washed, labeled proteins
retained on the beads were eluted, resolved by SDS-PAGE, and visualized
by storage phosphor autoradiography together with 10% of the total
radiolabeled receptor input used in each binding reaction.
C, incubations were performed as described in B
except that GST-PBX1b was used as the bait protein. These data are
representative of four experiments.
|
|
Pull-down assays were also carried out using GST-TR as the bait
protein. Consistent with results of experiments employing GST-PBX1a and
GST-PBX1b as bait proteins, 35S-labeled PBX1a and PBX1b
strongly interacted with GST-TR (Fig. 7). In contrast, a very weak interaction
was observed between 35S-labeled MEIS1 and GST-TR in the
absence or presence of unlabeled PBX1a. These data further demonstrate
that interactions between PBX1 proteins and TR are specific. In
contrast to results of experiments analyzing interactions between
GST-PBX1 proteins and 35S-labeled TR , interactions
between GST-TR and 35S-labeled PBX1 proteins were not
affected by the presence of T3. The latter observation suggests that
appending GST to the N terminus of TR blocks ligand-induced
conformational changes that facilitate interactions between TR and
PBX1 proteins.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 7.
TR strongly
interacts with PBX1a and PBX1b but not MEIS1. GST or GST-TR
immobilized on glutathione-Sepharose beads was incubated with in
vitro translated and 35S-labeled PBX1a, PBX1b, or
MEIS1 in the absence and presence of T3. An equimolar amount of
unlabeled MEIS1 was included in some incubations containing
35S-labeled PBX1a and PBX1b. After the matrix was
extensively washed, labeled proteins retained on the beads were eluted,
resolved by SDS-PAGE, and visualized by storage phosphor
autoradiography together with 10% of the total radiolabeled protein
input used in each binding reaction. Additional experimental details
are described under "Experimental Procedures."
|
|
To map the motifs in TR that interact with PBX1a, pull-down
experiments were conducted using various truncations of TR labeled with 35S in vitro. Deletion of the first 20 amino acids from the N terminus of TR had little or no effect on the
binding of TR to GST-PBX1a (Fig. 8).
Further deletion to amino acid 51 decreased the binding of TR to
GST-PBX1a. When deletion of the N terminus of TR was extended to
amino acid 120, binding of TR to GST-PBX1a was abolished. To analyze
further the interaction between TR and PBX1a, TR polypeptides
containing amino acids 1-157, amino acids 1-118, and amino acids
51-157 were tested for their ability to interact with GST-PBX1a. A
strong interaction was observed between GST-PBX1a and a TR
polypeptide containing amino acids 1-157. Markedly weaker but
detectable interactions were observed between GST-PBX1a and TR
polypeptides containing amino acids 1-118 and amino acids 51-157.
GST-PBX1b bound to TR truncations in a manner similar to that of
GST-PBX1a (data not shown). Collectively, these data suggest that a
TR region containing the DNA binding domain plus flanking sequences
(amino acids 21-157) is required for optimal binding to PBX1a and
PBX1b. Interestingly, interactions between GST-PBX1 fusion proteins and
TR truncations lacking the ligand binding domain were not enhanced
by the presence of T3. This observation is consistent with the scenario
that T3 binding to the ligand binding domain of TR causes a
conformational change that enhances the ability of the N-terminal
region of TR to interact with PBX1a and PBX1b.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 8.
A TR
region containing amino acids 21-157 is required for optimal
binding to PBX1a. A, the schematic representation of
TR . The DNA binding domain (DBD) and the ligand binding
domain (LBD) are indicated. Embedded within the LBD of TR
is a heptad repeat region involved in dimerization. A ligand-induced
change in the conformation of the LBD is responsible for providing an
interface for interaction with coactivator proteins. B,
wild-type and truncated forms of TR labeled with 35S by
in vitro translation were incubated with GST or GST-PBX1a
bound to glutathione-Sepharose beads. After the matrix was extensively
washed, labeled proteins retained on the beads were eluted, resolved by
SDS-PAGE, and visualized by storage phosphor autoradiography together
with 10% of the total radiolabeled protein input used in each binding
reaction.
|
|
Previous studies have shown that heterodimeric interactions between
PBX1 and MEIS1 are mediated by a PBX1 region containing a
3,4-isoleucine heptad repeat (26). This region is designated as the
MEIS cooperativity domain (MCD) and extends from amino acids 22 to 75 (Fig. 6A). To investigate whether TR interacted with a
PBX1 region that was separate from the MCD, we determined the ability
of N-terminal truncations of PBX1a to interact with GST-TR . Deletion
of the first 79 or 118 amino acids of PBX1a had no effect on the
binding of PBX1a to GST-TR (data not shown). These data indicate
that TR interacts with a PBX1 region that is distinct from that
mediating heterodimeric interactions with MEIS1.
 |
DISCUSSION |
Protein complexes containing PBX and MEIS1/PREP1 play a critical
role in embryonic development in both invertebrates and vertebrates (29-31). Although less is known about the functions of PBX-MEIS1/PREP1 in adult tissues, data from recent studies suggest that these complexes
are involved in controlling endocrine function. For example,
PBX-MEIS1 complexes mediate the stimulatory effects of cAMP on
transcription of 17 -hydroxylase cytochrome P450, a steroid hydroxylase involved in the production of steroid hormones from cholesterol (28, 37, 51). Other studies have shown that PBX-PREP1
complexes are involved in mediating the pancreatic-specific expression
of the genes for somatostatin (32) and glucagon (33). Still other
studies have demonstrated that interactions between PBX complexes and
the glucocorticoid receptor mediate the inhibitory effect of
glucocorticoids on prolactin transcription in non-pituitary cell lines
(38). In the present study, we show that PBX-MEIS1 complexes interact
with TR-RXR complexes to enhance T3 regulation of malic enzyme
transcription in avian hepatocytes. These studies are the first to
establish a role for PBX-MEIS1 in the control of thyroid hormone action.
Data from transfection (Figs. 4 and 5) and protein binding assays
(Figs. 6 and 7) suggest that stimulation of T3-induced malic enzyme
transcription by region E is mediated by direct interactions between
PBX-MEIS1 and TR-RXR. Due to the close proximity of region E to the
T3RU, PBX-MEIS1 may bind the malic enzyme gene as a tetrameric complex
with TR-RXR. In support of this possibility, peptide sequences mediating the interaction between PBX1a/b and TR are distinct from
those mediating interactions between PBX1a/b and MEIS1 (data not shown)
and between TR and RXR (Fig. 8). Furthermore, in gel mobility
shift assays, in vitro synthesized TR , RXR , PBX1a/b, and MEIS1 form a complex containing all four proteins on an
oligonucleotide probe consisting of T3RE-2 linked to region E (data not
shown). Because the formation of this tetrameric complex is not
associated with any changes in the total binding of TR -RXR and
PBX1a/b-MEIS1 to the probe, the mechanism by which region E modulates
T3 responsiveness does not appear to involve alterations in DNA
binding. Previous studies have shown that the stimulatory effects of T3
on transcription are mediated by the recruitment of coactivator
proteins to the TR (10, 52). Coactivators of TR may regulate
transcription by directly interacting with the basal transcriptional
machinery, by modulating interactions between TR and the basal
transcriptional machinery, and by modifying chromatin structure.
Complex formation between TR-RXR and PBX-MEIS1 may augment T3-induced
malic enzyme transcription by facilitating the recruitment of
coactivators to the malic enzyme promoter.
A role for PBX-MEIS1 complexes in modulating the T3 responsiveness of
the malic enzyme gene may be conserved in humans. Sequence comparison
analysis of the human malic enzyme gene indicates the presence of a
putative PCE at 140/ 124 bp. This PCE is located immediately
upstream of a previously described T3RE at 105/ 87 bp (53) and is
composed of consecutive tetrameric half-sites (TGAT and TGAC) separated
by a 9-bp spacer. González-Manchón et al. (53)
have shown that the region containing the putative PCE enhances T3
responsiveness conferred by the T3RE at 105/ 87.
A role for accessory DNA binding factors in modulating T3
responsiveness has been described for other genes. For example, the
T3-induced stimulation of the phosphoenolpyruvate carboxykinase promoter in hepatoma cells is mediated by a T3RE and a sequence that
binds the liver-enriched factors, C/EBP and C/EBP (54). In
primary hepatocyte cultures, T3 stimulation of the S14 gene requires the presence of T3REs located between 2700 and 2500 bp and
a nuclear factor Y-binding site near the transcription start site (55).
Increased T3 responsiveness of the rat growth hormone promoter in
pituitary cells relative to non-pituitary cells is mediated by a
synergistic interaction between TR and the pituitary-specific
DNA-binding protein, Pit-1 (also referred to as GHF-1) (56). Physical
interactions between Pit-1 and TR enhance the binding of TR to the rat
growth hormone promoter (57). In cardiac muscle cells, myocyte-specific
enhancer factor 2 potentiates the ability of TR to stimulate
-cardiac myosin heavy chain transcription in the presence of T3
(58). Protein binding assays indicate that myocyte-specific enhancer
factor 2 and TR specifically bind each other. Collectively, these
findings and the results of the present study indicate that a wide
variety of transcription factors can interact with TR on promoters of
T3-responsive genes. Such factors expand the dynamic range of T3
responsiveness and constitute an important mechanism by which T3
regulates transcription in a tissue- or cell type-specific manner.
Complexes containing PBX-MEIS1/PREP1 have been shown to function as
accessory proteins for other transcription factors besides TR. For
example, on the urokinase plasminogen activator promoter, PBX-PREP1
binds a cooperation mediating element that is positioned between an
activator protein-1 (AP-1) site and a combined PEA3/AP-1 site (25, 59).
Binding of PBX-PREP1 to the cooperation mediating element is required
for synergistic activation of urokinase plasminogen activator
transcription by the AP-1 and PEA3/AP-1 sites. The elastase I promoter
contains a PBX-binding site that consists of part of an enhancer
element conferring cell type-specific regulation of transcription (34,
60). In pancreatic acinar cells, this PBX-binding site potentiates the
transcriptional activity of an adjacent element that binds the
pancreatic acinar cell-specific factor, PTF-1. The somatostatin
promoter contains adjacent binding sites for PBX-PREP1 and the
pancreatic cell-specific factor, PDX1 (32). PBX-PREP1 alone is devoid
of transcriptional activity but interacts with PDX1 to stimulate a
10-fold increase in somatostatin promoter activity. This functional
interaction between PBX-PREP1 and PDX1 is not mediated by alterations
in the binding of PBX-PREP1 and PDX1 to the somatostatin promoter.
E2a-MyoD heterodimers in muscle cell nuclear extracts bind to E box
motifs that are flanked at their 5' end by a PCE (50). In transfection
assays, the binding of PBX-MEIS1 to the PCE enhances transcriptional
activation by E2a-MyoD bound to the adjacent E box motif. In contrast
to the interaction between PBX-PREP1 and PDX1 on the somatostatin
promoter and the interaction between PBX-MEIS1 and TR-RXR on the malic enzyme promoter, the interaction between PBX-MEIS1 and E2a-MyoD on the
PCE/E-box element is mediated, in part, by alterations in protein
binding to DNA. These studies indicate that PBX-MEIS1/PREP1 complexes
functionally interact with a wide variety transcription factors and
that the mechanisms mediating these interactions vary depending on the
nature of the proteins that interact with PBX-MEIS1/PREP1.
The results of the present study are the first to establish a role for
PBX and MEIS1 in the control of gene transcription in hepatocytes.
PBX1-MEIS complexes may regulate the transcription of other genes in
liver besides malic enzyme. For example, the AC element of the
phosphoenolpyruvate carboxykinase promoter contains a sequence ( 255
to 248 bp) that perfectly matches the consensus PCE, TGATTGAC.
Mutation of the AC element abrogates the effects of cAMP and insulin on
phosphoenolpyruvate carboxykinase transcription in H4IIe hepatoma cells
(61). There are no reports addressing whether PBX-MEIS1 binds to the AC
element. Additional experimentation will be needed to determine whether
PBX-MEIS1 complexes play a broader role in the regulation of genes
involved in carbohydrate and lipid metabolism in liver.
Several coactivators of TR have been identified that enhance
T3-dependent transcriptional activation by physically
interacting with the ligand binding domain (LBD) of TR. Examples of
such proteins include CREB-binding protein (62) and steroid receptor
coactivator 1 (63). T3-dependent transcriptional activation
is also controlled by nuclear proteins that physically interact with TR
regions distinct from the LBD. For example, the general transcription
factor, TFIIB, facilitates T3-dependent transcriptional
activation by interacting with a 10-amino acid sequence in the A/B
region of TR (64). Myocyte-specific enhancer factor 2 and the
hematopoietic basic ZIP protein p45/NF-E2 enhance
T3-dependent transcriptional activation by interacting with
the DNA binding domain of TR (58, 65). Results from the present study
demonstrating that PBX1a/b interacts with sequences in the A/B region
and DNA binding domain of TR provide further support for a role of
TR regions distinct from the LBD in modulating T3-dependent
transcriptional activation.
Results from DNA binding analyses (Fig. 3) indicate that region E
contains a novel PCE that binds PBX-MEIS1 heterodimeric complexes in
three different configurations. One configuration is composed of tandem
half-sites separated by a 7-bp spacer (i.e. half-sites 1 and
4) and the other two configurations are composed of tandem half-sites
with no spacer sequence (i.e. half-sites 1 and 2 and
half-sites 3 and 4). Results from transfection experiments suggest that
all three binding configurations contribute to the stimulation of T3
responsiveness by region E with binding to half-sites 1 and 4 making
the greatest contribution. Interestingly, site-specific mutations of
region E that restricted PBX-MEIS1 binding to half-sites 1 and 4 (mut E
2/3) or half-sites 3 and 4 (mut E 1/2) had no effect on the DNA binding
affinity yet conferred a smaller increase in T3 responsiveness than
wild-type region E. This observation suggests that sequences flanking
the half-sites and/or the distance between the half-sites can modulate
the functional activity of PBX-MEIS1 complexes without altering their
ability to bind DNA.
We previously reported that region E was one of four cis-acting
elements mediating differences in T3 regulation of malic enzyme transcription between chick embryo hepatocytes and chick embryo fibroblasts (15). This conclusion was based on the finding that mutation of region E markedly inhibited T3 regulation of malic enzyme
transcription in chick embryo hepatocytes but had no effect on T3
regulation in chick embryo fibroblasts. Cell type-dependent differences in region E activity are probably not due to alterations in
expression of PBX and MEIS1, as these proteins are expressed in a wide
variety of tissues (17, 18, 36, 40). This supposition is supported by
data from gel mobility shift assays demonstrating that the pattern and
extent of protein binding to region E in chick embryo fibroblasts is
similar to that observed in chick embryo hepatocytes (15). We postulate
that the difference in region E activity between chick embryo
hepatocytes and chick embryo fibroblasts is mediated by a
post-translational mechanism. One possibility is that PBX-MEIS1
interacts with an activator or inhibitor whose activity varies in
different cell types. In support of this possibility, Abramovich
et al. (66) have recently identified a novel PBX-interacting
protein that inhibits the ability of PBX complexes to bind DNA and
activate transcription. Further studies are needed to determine the
role of this protein in mediating differences in T3 responsiveness
between chick embryo hepatocytes and chick embryo fibroblasts.
In summary, the present study establishes a role for
PBX-MEIS1 complexes in conferring optimal T3 regulation of malic enzyme transcription in liver. Stimulation of T3-induced transcription by
PBX-MEIS1 may by mediated by physical interactions between PBX and TR.
The observation that PBX-MEIS1 heterodimers functionally and physically
interact with TR provides further support for the proposal that
PBX-MEIS1 heterodimers serve as accessory transcription factors
in the developmental and hormonal regulation of gene expression (50).
 |
ACKNOWLEDGEMENTS |
We thank Drs. M. Kamps (PBX1a and PBX1b
cDNA and PBX antiserum), N. Copeland (MEIS1 cDNA), C. Murre
(PBX1a truncations), and S. Antonarakis and H. Chen (PREP1/pKnox
cDNA) for supplying us with the reagents indicated in parentheses.
 |
FOOTNOTES |
*
This work was supported by Established Investigator Award
9940007N from the American Heart Association.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of
Biochemistry, P. O. Box 9142, West Virginia University, Morgantown, WV 26506-9142. Tel.: 304-293-7751, Fax: 304-293-6846, E-mail:
fbhillgartner@hsc.wvu.edu.
Published, JBC Papers in Press, April 30, 2001, DOI 10.1074/jbc.M102166200
 |
ABBREVIATIONS |
The abbreviations used are:
T3, 3,5,3'-triiodo-L-thyronine;
TR, nuclear T3 receptor;
RXR, retinoid X receptor;
CAT, chloramphenicol acetyltransferase;
T3RE, triiodothyronine response element;
T3RU, triiodothyronine response
unit;
GST, glutathione S-transferase;
LBD, ligand binding
domain;
PCE, PBX-cooperativity element;
MCD, MEIS cooperativity domain;
C/EBP, CCAAT/enhancer-binding protein;
AP-1, activator protein-1;
PAGE, polyacrylamide gel electrophoresis;
bp, base pair.
 |
REFERENCES |
| 1.
|
Goodridge, A. G.
(1968)
Biochem. J.
108,
663-666
|
| 2.
|
Goodridge, A. G.
(1968)
Biochem. J.
108,
667-673
|
| 3.
|
Goodridge, A. G.,
and Adelman, T. G.
(1976)
J. Biol. Chem.
251,
3027-3032
|
| 4.
|
Hillgartner, F. B.,
and Charron, T.
(1998)
Am. J. Physiol.
274,
E493-E501
|
| 5.
|
Roncero, C.,
and Goodridge, A. G.
(1992)
J. Biol. Chem.
267,
14918-14927
|
| 6.
|
Ma, X.-J.,
Salati, L. M.,
Ash, S. E.,
Mitchell, D. A.,
Klautky, S. A.,
Fantozzi, D. A.,
and Goodridge, A. G.
(1990)
J. Biol. Chem.
265,
18435-18441
|
| 7.
|
Salati, L. M.,
Ma, X.-J.,
McCormick, C. C.,
Stapleton, S. R.,
and Goodridge, A. G.
(1991)
J. Biol. Chem.
266,
4010-4016
|
| 8.
|
Hillgartner, F. B.,
Chen, W.,
and Goodridge, A. G.
(1992)
J. Biol. Chem.
267,
12299-12306
|
| 9.
|
Samuels, H. H.,
Forman, B. M.,
Horowitz, Z. D.,
and Ye, Z. S.
(1989)
Annu. Rev. Physiol.
51,
623-639
|
| 10.
|
Zhang, J.,
and Lazar, M. A.
(2000)
Annu. Rev. Physiol.
62,
439-466
|
| 11.
|
Desvergne, B.
(1994)
Mol. Cell. Endocrinol.
100,
125-131
|
| 12.
|
Hodnett, D. W.,
Fantozzi, D. A.,
Thurmond, D. C.,
Klautky, S. A.,
MacPhee, K. G.,
Estrem, S. T.,
Xu, G.,
and Goodridge, A. G.
(1996)
Arch. Biochem. Biophys.
334,
309-324
|
| 13.
|
Thurmond, D. C.,
and Goodridge, A. G.
(1998)
J. Biol. Chem.
273,
1613-1622
|
| 14.
|
Fang, X.,
and Hillgartner, F. B.
(2000)
Mol. Cell. Endocrinol.
164,
41-52
|
| 15.
|
Fang, X.,
and Hillgartner, F. B.
(1998)
Arch. Biochem. Biophys.
349,
138-152
|
| 16.
|
Burglin, T. R.
(1997)
Nucleic Acids Res.
25,
4173-4180
|
| 17.
|
Kamps, M. P.,
Murre, C.,
Sun, X. H.,
and Baltimore, D.
(1990)
Cell
60,
547-555
|
| 18.
|
Nourse, J.,
Mellentin, J. D.,
Galili, N.,
Wilkinson, J.,
Stanbridge, E.,
Smith, S. D.,
and Cleary, M. L.
(1990)
Cell
60,
535-545
|
| 19.
|
Peifer, M.,
and Wieschaus, E.
(1990)
Genes Dev.
4,
1209-1223
|
| 20.
|
Popperl, H.,
Rikhof, H.,
Chang, H.,
Haffter, P.,
Kimmel, C. B.,
and Moens, C. B.
(2000)
Mol. Cell
6,
255-267
|
| 21.
|
Lumsden, A.,
and Krumlauf, R.
(1996)
Science
274,
1109-1115
|
| 22.
|
Chang, C.-P.,
Shen, W.-F.,
Rozenfeld, S.,
Lawrence, H. J.,
Largman, C.,
and Cleary, M.
(1995)
Genes Dev.
9,
663-674
|
| 23.
|
van Dijk, M. A.,
and Murre, C.
(1994)
Cell
78,
617-624
|
| 24.
|
Lu, Q.,
Knoepfler, P.,
Scheele, J.,
Wright, D. D.,
and Kamps, M. P.
(1995)
Mol. Cell. Biol.
15,
3786-3795
|
| 25.
|
Berthelsen, J.,
Zappavigna, V.,
Mavilio, F.,
and Blasi, F.
(1998)
EMBO J.
17,
1423-1433
|
| 26.
|
Knoepfler, P. S.,
Calvo, K. R.,
Chen, H.,
Antonarakis, S. E.,
and Kamps, M. P.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
14553-14558
|
| 27.
|
Chang, C. P.,
Jacobs, Y.,
Nakamura, T.,
Jenkins, N. A.,
Copeland, N. G.,
and Cleary, M. L.
(1997)
Mol. Cell. Biol.
17,
5679-5687
|
| 28.
|
Bischof, L. J.,
Kagawa, N.,
Moskow, J. J.,
Takahashi, Y.,
Iwamatsu, A.,
Buchberg, A. M.,
and Waterman, M. R.
(1998)
J. Biol. Chem.
273,
7941-7948
|
| 29.
|
Casares, F.,
and Mann, R.
(1998)
Nature
392,
723-726
|
| 30.
|
Toresson, H.,
Parmar, M.,
and Campbell, K.
(2000)
Mech. Dev.
94,
183-187
|
| 31.
|
Ferretti, E.,
Marshall, H.,
Popperl, H.,
Maconochie, M.,
Krumlauf, R.,
and Blasi, F.
(2000)
Development
127,
155-166
|
| 32.
|
Goudet, G.,
Delhalle, S.,
Biemar, F.,
Martial, J. A.,
and Peers, B.
(1999)
J. Biol. Chem.
274,
4067-4073
|
| 33.
|
Herzig, S.,
Fuzesi, L.,
and Knepel, W.
(2000)
J. Biol. Chem.
275,
27989-27999
|
| 34.
|
Swift, G. H.,
Liu, Y.,
Rose, S. D.,
Bischof, L. J.,
Steelman, S.,
Buchberg, A. M.,
Wright, C. V.,
and MacDonald, R. J.
(1998)
Mol. Cell. Biol.
18,
5109-5120
|
| 35.
|
Penkov, D.,
Tanaka, S.,
Di Rocco, G.,
Berthelsen, J.,
Blasi, F.,
and Ramirez, F.
(2000)
J. Biol. Chem.
275,
16681-16689
|
| 36.
|
Monica, K.,
Galili, N.,
Nourse, J.,
Saltman, D.,
and Cleary, M. L.
(1991)
Mol. Cell. Biol.
11,
6149-6157
|
| 37.
|
Ogo, A.,
Waterman, M. R.,
and Kagawa, N.
(1997)
Arch. Biochem. Biophys.
338,
193-200
|
| 38.
|
Subramaniam, N.,
Cairns, W.,
and Okret, S.
(1998)
J. Biol. Chem.
273,
23567-23574
|
| 39.
|
Ferretti, E.,
Schulz, H.,
Talarico, D.,
Blasi, F.,
and Berthelsen, J.
(1999)
Mech. Dev.
83,
53-64
|
| 40.
|
Smith, J. E.,
Bollekens, J. A.,
Inghirami, G.,
and Takeshita, K.
(1997)
Genomics
43,
99-103
|
| 41.
|
Horton, R. M.,
Cai, Z.,
Ho, S. N.,
and Pease, L. R.
(1990)
BioTechniques
8,
528-535
|
| 42.
|
Goodridge, A. G.
(1973)
J. Biol. Chem.
248,
1924-1931
|
| 43.
|
Baillie, R. A.,
Klautky, S. A.,
and Goodridge, A. G.
(1993)
J. Nutr. Biochem.
4,
431-439
|
| 44.
|
Gorman, C. M.,
Moffat, L. F.,
and Howard, B. H.
(1982)
Mol. Cell. Biol.
2,
1044-1055
|
| 45.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning, A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 46.
|
Ausubel, F. M.,
Brent, R.,
Kingston, R. E.,
Moore, D. D.,
Seidman, J. G.,
Smith, J. A.,
and Struhl, K.
(1995)
Current Protocols in Molecular Biology
, pp. 12.1.1-12.1.9, John Wiley & Sons, Inc., New York
|
| 47.
|
Knoepfler, P. S.,
and Kamps, M. P.
(1997)
Oncogene
14,
2521-2531
|
| 48.
|
Smith, D. B.,
and Johnson, K. S.
(1988)
Gene (Amst)
67,
31-40
|
| 49.
|
Jacobs, Y.,
Schnabel, C. A.,
and Cleary, M. L.
(1999)
Mol. Cell. Biol.
19,
5134-5142
|
| 50.
|
Knoepfler, P. S.,
Bergstrom, D. A.,
Uetsuki, T.,
Dac-Korytko, I.,
Sun, Y. H.,
Wright, W. E.,
Tapscott, S. J.,
and Kamps, M. P.
(1999)
Nucleic Acids Res.
27,
3752-3761
|
| 51.
|
Ogo, A.,
Waterman, M. R.,
McAllister, J. M.,
and Kagawa, N.
(1997)
Arch. Biochem. Biophys.
348,
226-231
|
| 52.
|
Glass, C. K.,
and Rosenfeld, M. G.
(2000)
Genes Dev.
14,
121-141
|
| 53.
|
González-Manchón, C.,
Ayuso, M. S.,
and Parrilla, R.
(1999)
Gene (Amst)
226,
111-119
|
| 54.
|
Park, E. A.,
Song, S.,
Vinson, C.,
and Roesler, W. J.
(1999)
J. Biol. Chem.
274,
211-217
|
| 55.
|
Jump, D. B.,
Badin, M. V.,
and Thelen, A.
(1997)
J. Biol. Chem.
272,
27778-27786
|
| 56.
|
Schaufele, F.,
West, B. L.,
and Baxter, J. D.
(1992)
Mol. Endocrinol.
6,
656-665
|
| 57.
|
Palomino, T.,
Sanchez-Pacheco, A.,
Pena, P.,
and Aranda, A.
(1998)
FASEB J.
12,
1201-1209
|
| 58.
|
Lee, Y.,
Nadal-Ginard, B.,
Mahdavi, V.,
and Izumo, S.
(1997)
Mol. Cell. Biol.
17,
2745-2755
|
| 59.
|
Berthelsen, J.,
Vandekerkhove, J.,
and Blasi, F.
(1996)
J. Biol. Chem.
271,
3822-3830
|
| 60.
|
Kruse, F.,
Rose, S. D.,
Swift, G. H.,
Hammer, R. E.,
and MacDonald, R. J.
(1995)
Mol. Cell. Biol.
15,
4385-4394
|
| 61.
|
Yeagley, D.,
Moll, J.,
Vinson, C. A.,
and Quinn, P. G.
(2000)
J. Biol. Chem.
275,
17814-17820
|
| 62.
|
Chakravarti, D.,
LaMorte, V. J.,
Nelson, M. C.,
Nakajima, T.,
Schulman, I. G.,
Juguilon, H.,
Montminy, M.,
and Evans, R. M.
(1996)
Nature
383,
99-103
|
| 63.
|
Onate, S. A.,
Tsai, S. Y.,
Tsai, M. J.,
and O'Malley, B. W.
(1995)
Science
270,
1354-1357
|
| 64.
|
Hadzic, E.,
Desai-Yajnik, V.,
Helmer, E.,
Guo, S.,
Wu, S.,
Koudinova, N.,
Casanova, J.,
Raaka, B. M.,
and Samuels, H. H.
(1995)
Mol. Cell. Biol.
15,
4507-4517
|
| 65.
| Cheng, X., Reginato, M. J., Andrews, N. C., and Lazar,
M. A. (1997) Mol. Cell. Biol. 1407-1416
|
| 66.
|
Abramovich, C.,
Shen, W. F.,
Pineault, N.,
Imren, S.,
Montpetit, B.,
Largman, C.,
and Humphries, R. K.
(2000)
J. Biol. Chem.
275,
26172-26177
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Jackson-Hayes, S. Song, E. N. Lavrentyev, M. S. Jansen, F. B. Hillgartner, L. Tian, P. A. Wood, G. A. Cook, and E. A. Park
A Thyroid Hormone Response Unit Formed between the Promoter and First Intron of the Carnitine Palmitoyltransferase-Ialpha Gene Mediates the Liver-specific Induction by Thyroid Hormone
J. Biol. Chem.,
February 28, 2003;
278(10):
7964 - 7972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Gregory and P. I. Mackenzie
The Homeodomain Pbx2-Prep1 Complex Modulates Hepatocyte Nuclear Factor 1alpha -Mediated Activation of the UDP-Glucuronosyltransferase 2B17 Gene
Mol. Pharmacol.,
July 1, 2002;
62(1):
154 - 161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Yin, Y. Zhang, and F. B. Hillgartner
Sterol Regulatory Element-binding Protein-1 Interacts with the Nuclear Thyroid Hormone Receptor to Enhance Acetyl-CoA Carboxylase-alpha Transcription in Hepatocytes
J. Biol. Chem.,
May 24, 2002;
277(22):
19554 - 19565.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|